***Pharmaceutical Benefits Advisory Committee***

Email: PBAC@health.gov.au Address all mail to:

PBAC Secretariat

GPO Box 9848

Canberra ACT 2601

**DELISTING OF PHARMACEUTICAL BENEFIT ITEMS**

**EFFECTIVE 01 MAY 2024**

Following is the advice of the Pharmaceutical Benefits Advisory Committee concerning the delisting of items from the declaration under subsections 85(2) and 85(2A) of the *National Health Act* *1953*, with effect from the above date.

|  |  |
| --- | --- |
| **Item** | **PBAC Advice** |
| Carbomer 974 | The sponsor requested the delisting of Poly Gel® (carbomer 974) from the Pharmaceutical Benefits Scheme (PBS).  The PBAC noted the relatively low number of services in the last financial year and that there are multiple alternatives on the PBS. The PBAC advised the delisting of this product would not result in an unmet clinical need. |
| Procaine benzylpenicillin | The sponsor requested the delisting of Cilicaine® (procaine benzylpenicillin) from the PBS.  The PBAC noted the low number of services in the last financial year. The PBAC considered that, while there are alternatives available on the PBS for the treatment of non-syphilis indications, there are no suitable alternatives for the treatment of syphilis. The PBAC advised the delisting of this product may result in an unmet clinical need. The Department sought to retain the product in line with this advice, however the sponsor indicated retention was unviable due to technical manufacturing problems and wished to proceed with the delisting. |



Vanessa McMahon

Director, PBAC Assessment Section

Office of Health Technology Assessment

Technology Assessment and Access Division

18 April 2024